Otrivin Duo (Xylometazoline Hydrochloride, Ipratropium Bromide)

Xylometazoline hydrochloride, the active ingredient in Otrivin Duo, is an alpha‑adrenergic agonist presented as a nasal spray for nasal use. It reduces nasal congestion and excessive nasal discharge in adults and children. Ipratropium bromide, also present, adds anticholinergic activity to further control secretions. GNH USA supplies Otrivin Duo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Otrivin Duo combines an alpha‑adrenergic agonist and an anticholinergic to address nasal airway obstruction and secretions.

- Nasal congestion: provides rapid decongestion by constricting nasal blood vessels. - Runny nose: decreases watery nasal discharge by blocking muscarinic receptors. - Allergic rhinitis: alleviates blockage and rhinorrhea associated with allergic inflammation.

Adverse reactions may occur with nasal spray use.

Common Side Effects: - Nasal irritation or burning sensation. - Dryness of the nasal mucosa. - Sneezing. - Headache. - Taste disturbance. - Cough.

Serious or Rare Side Effects: - Persistent nasal bleeding. - Severe allergic reaction (anaphylaxis, angioedema). - Hypertension exacerbation. - Cardiac arrhythmia. - Vision changes. - Rebound congestion with prolonged use.

Use Otrivin Duo according to professional guidance and observe the following precautions.

- Duration of use: limit to no more than 7 consecutive days to avoid rebound congestion. - Underlying conditions: avoid if you have severe hypertension, coronary artery disease, or glaucoma. - Age restrictions: consult a healthcare professional before use in children under 6 years. - Concomitant nasal medications: do not combine with other vasoconstrictive nasal sprays without advice. - Pregnancy and lactation: discuss potential risks with a physician before use. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Consider potential drug interactions when using Otrivin Duo.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): may increase hypertensive risk. - Other nasal decongestants: additive vasoconstrictive effects can raise blood pressure.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: monitor blood pressure as vasoconstriction may counteract therapy. - Anticholinergic drugs: increased anticholinergic load may cause dry mouth or blurred vision. - Beta‑blockers: may blunt cardiovascular response to alpha‑adrenergic stimulation.